Next Article in Journal
A Simulation-Based Methodology of Developing 3D Printed Anthropomorphic Phantoms for Microwave Imaging Systems
Next Article in Special Issue
Pancreatic Ductal Adenocarcinoma: Epidemiology and Risk Factors
Previous Article in Journal
Deformation Parameters of the Heart in Endurance Athletes and in Patients with Dilated Cardiomyopathy—A Cardiac Magnetic Resonance Study
Previous Article in Special Issue
Clinical Analysis of Early-Stage Pancreatic Cancer and Proposal for a New Diagnostic Algorithm: A Multicenter Observational Study
 
 
Review
Peer-Review Record

Molecular Approaches Using Body Fluid for the Early Detection of Pancreatic Cancer

Diagnostics 2021, 11(2), 375; https://doi.org/10.3390/diagnostics11020375
by Kennichi Satoh
Reviewer 1:
Reviewer 2: Anonymous
Diagnostics 2021, 11(2), 375; https://doi.org/10.3390/diagnostics11020375
Submission received: 20 January 2021 / Revised: 12 February 2021 / Accepted: 17 February 2021 / Published: 22 February 2021
(This article belongs to the Special Issue Diagnosis of Pancreatic Cancer)

Round 1

Reviewer 1 Report

The review is informative, but poorly structured and many typos.

Line 48 - maybe this is point 2.

In general, I would rather name the sub-points on the biological fluid under study. Can genetic mutations be detected in saliva?

Lines 357-421 - Template not deleted.

In conclusion, it is necessary to discuss the limitations of the use of these biological fluids in more detail.

Author Response

I very much appreciate for your comments and suggestions.

I have re-edited the manuscript according to your comments and suggestions and responses to your comments and suggestions are summarized as below.

 

# Line 48 - maybe this is point 2

I very much appreciate for your identification. I have corrected “1.2” to “2 “in line 48.

 

 

# In general, I would rather name the sub-points on the biological fluid under study. 

I very much appreciate for your suggestion.  I have corrected “4” to “3.4” in line 284.

 

 

# Can genetic mutations be detected in saliva?

Germline mutations have found in samples from saliva and have been examined for hereditary cancer risk assessment including pancreatic cancer.  Thus, I have added this description (lines 288 to 289) and reference (ref no. 54).

 

 

# Lines 357-421 - Template not deleted.

I very much appreciate for your identification.  I have deleted template.

 

 

# In conclusion, it is necessary to discuss the limitations of the use of these biological fluids in more detail.

I very much appreciate for your suggestion.  I have added the limitations and related description in the conclusion (Lines 344-345, and, lines 347 to 349).

Author Response File: Author Response.docx

Reviewer 2 Report

This paper is a very well-organized review for the early detection of pancreatic cancer. Here are some minor comments.

  1. Line 48, 1.2. Gene mutation analysis in pancreatic juice -> 2. Gene mutation analysis in pancreatic juice
  2. Line 357 2. Material and Methods -> remove
  3. Table 1. Please match the rows and columns. It is difficult to see.
  4. Table 1. Candidate biomarkers: KRAS is duplicated.
  5. Serum biomarker signature is a tenable approach to detecting early state PDAC (J Clin Oncol 36:2887-2894). Could you introduce the related studies?

Author Response

I very much appreciate for your comments and suggestions.

I have re-edited the manuscript according to your comments and suggestions, and responses to your comments and suggestions are summarized as below.

 

  1. Line 48, 1.2. Gene mutation analysis in pancreatic juice -> 2. Gene mutation analysis in pancreatic juice

  I very much appreciate for your identification.  I have made correction in line 48.

 

  1. Line 357 2. Material and Methods -> remove

I very much appreciate for your identification.  I have removed the section you pointed out.

 

  1. Table 1. Please match the rows and columns. It is difficult to see.

I very much appreciate for your comments.  I have re-edited the Table 1 in the revised manuscript.

 

  1. Table 1. Candidate biomarkers: KRAS is duplicated.

I very much appreciate for your identification.  I would like to mean that KRAS is candidate biomarker in both pancreatic juice and blood.  Thus, I have description the materials as bold to avoid confusion.

 

  1. Serum biomarker signature is a tenable approach to detecting early state PDAC (J Clin Oncol 36:2887-2894). Could you introduce the related studies?

 

I have introduced this excellent study in line 151 to 153 and added the reference (ref no. 30).

Author Response File: Author Response.docx

Round 2

Reviewer 1 Report

The authors responded to all the comments of the reviewer and made corrections to the text of the manuscript. I believe that the article in its current form can be accepted for publication.

Back to TopTop